AMSA Scorecard

	University of Wisconsin School of Medicine and Public Health
	City: Madison	State: WI
Links: Commentary: A reassessment including a review of newly submitted policies has increased the grade of University of Wisconsin School of Medicine and Public Health (UW SMPH) from a D to a B. UW SMPH possesses strong policies regulating industry interaction, including, notably, a commendable policy on samples, replacing them with vouchers to serve patients while providing equal access to generic medications. UW SMPH also has a comprehensive annual disclosure policy and an in-depth review procedure for certain key staff and researchers.

Gifts & Meals		This institution has strong policies prohibiting the provision of on-site meals by industry and substantially limiting gifting. However, certain exceptions for educational gifts allow pharmaceutical marketing to continue to exert inappropriate influence on prescribing behavior. *This institutional ban on meals was missed in our original assessment.
Consulting relationships		The institution has a detailed and rigorous review process in place for faculty with external relationships who are also involved in federally-funded research or human subjects research. However faculty not involved in such research who may have extensive external industry relationships do not qualify for review. In addition, the institution does not have policy language requiring all consulting relationships be described in an official contract, or that payment is commensurate to the task. Such provisions only exist for researchers.
Industry-funded speaking relationships		The institution does not have a policy that limits long-term external speaking relationships with industry. However, an encompassing annual disclosure process does capture all existent speaking relationships among faculty and reviews some of those relationships (those of faculty in federally-funded or human subjects research.)
Disclosure		Institution staff must annually disclose all external relationships.
Pharmaceutical samples		This institution bans samples in all inpatient clinics and has established specific and very restrictive policies for their use in outpatient settings – specifically a voucher system has been instituted that provides equal access to both generic and brand-name medication. However, vouchers for brand-name medication may still be given directly to doctors by sales representatives.
Purchasing & Formularies		Members of purchasing or formulary committees may not participate in decisions wherein they have possible conflicts of interest.
Site Access		The institution requires vendors to have an appointment before accessing the site, and expressly prohibits cold calling or soliciting an appointment. Vendors are also prohibited from patient care areas unless permission is obtained in advance from the patient and management.
On-campus Education		The School of Medicine requires that CME content be free of commercial influence and has put in place a review system to ensure educational programs are free of commercial bias. In addition, the institution's extensive CME policy states that all industry support is free of industry control, but no policy was provided relatiing to industry involvement in other educational non-accredited events.
Attendance at Industry-Sponsored Lectures & Meetings Off-Campus		The institution prohibits the payment of honoraria for meeting attendance, but this policy applies only to CME events sponsored by UW SMPH, not to off-site, industry-sponsored events. An additional CME policy on managing COI restricts faculty behavior off-site, but only applies to faculty involved in the planning of UW SMPH CME events, not faculty or students as a whole.
Industry Support for Scholarships & Funds for Trainees		The institution requires grants and scholarships to be unrestricted, and requires that the office of the Associate Dean for Students select the student recipients.
Medical school curriculum		A new policy on student/industry interaction outlines a thorough curricular requirement for medical students covering industry marketing tactics and effects of interaction on behavior and prescribing.
Do the policies specify an oversight mechanism?		These policies cite responsible parties for oversight of CME conflicts of interest policies.
Are there explicit sanctions for noncompliance?		These policies outline sanctions for noncompliance with the CME conflicts of interest policies.


	Model policy
	Good progress toward model policy
	No policy, or policy unlikely to have a substantial effect on behavior
	Did not report
	Policy not relevant to this institution (e.g., does not make purchasing decisions)